XML 98 R73.htm IDEA: XBRL DOCUMENT v3.25.4
LICENSE, COLLABORATION AND OTHER REVENUE - TPC Collaboration Agreement - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 11, 2015
USD ($)
performance_obligation
Jun. 30, 2013
USD ($)
performance_obligation
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues         $ 236,196,000 $ 160,180,000 $ 194,623,000
Accounts receivable, net         47,031,000 34,368,000  
Payables         21,185,000 15,180,000  
Revenue recognized         0 0 3,738,000
Tanabe Pharma Corporation | License Collaboration And Other Revenue, Royalties              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues $ 8,700,000       1,800,000 1,900,000 2,000,000.0
Tanabe Pharma Corporation | Regulatory Milestone Payments              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Milestone revenue $ 25,000,000.0       25,000,000.0    
Total revenues     $ 15,000,000.0 $ 10,000,000.0      
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaboration agreement, expiration period 10 years            
Termination of agreement by counterparty, written notice period (in months) 12 months            
Number of performance obligations | performance_obligation 2            
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement | Development Milestones              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Milestone revenue $ 10,000,000.0            
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of royalty payments on sales 20.00%            
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement | Maximum | Development, Regulatory and Commercial Events              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Potential milestone revenue $ 225,000,000.0            
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement | Maximum | Regulatory Milestone Payments              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Eligible milestone payments (up to) 40,000,000.0            
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement | Maximum | Commercial Milestone Payments              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Potential milestone revenue (up to) $ 175,000,000.0            
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement | Minimum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of royalty payments on sales 13.00%            
Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Milestone revenue $ 10,000,000.0            
Upfront cash payment received 20,000,000.0            
Incurred clinical and commercial development cost 20,500,000            
Cost of research services $ 20,500,000            
Accounts receivable, net         0    
Deferred revenue         0    
Payables         0    
Contact asset         500,000    
Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Accounts receivable, net         0    
Deferred revenue         0    
Revenue recognized         1,000,000.0 700,000 3,700,000
Other current liabilities         0    
JT and Torii | Sublicense Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues         5,700,000 5,400,000 5,400,000
Number of performance obligations | performance_obligation   2          
Accounts receivable, net         1,500,000    
Potential payment for achievement of annual net sales milestones   $ 55,000,000.0          
License agreement, notice period for termination   6 months          
Prior written notice for termination on the breach of agreement period   60 days          
Medice | License Collaboration And Other Revenue, Royalties              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues         100,000 0 0
Medice | Amended Supply Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues         0 0 0
Medice | Supply Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues         300,000 $ 0 $ 0
Accounts receivable, net         300,000    
Deferred revenue         0    
Payables         $ 0